title: Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.
abstract: FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84% anaplastic large cell lymphoma and 65% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.
authors.affiliation: Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, UK.
authors.forename: Suketu
authors.initials: S
authors.lastname: Patel
authors.affiliation: Center for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland. ; School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland. ; Royal College of Surgeons in Ireland, Dublin, Ireland.
authors.forename: Derek
authors.initials: D
authors.lastname: Murphy
authors.affiliation: Department of Pathology, University of Wüerzburg, Wüerzburg, Germany.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Haralambieva
authors.affiliation: Department of Microbiology and Immunology, College of Medicine, University of Mosul, Iraq.
authors.forename: Zainalabideen A
authors.initials: ZA
authors.lastname: Abdulla
authors.affiliation: Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
authors.forename: Kah Keng
authors.initials: KK
authors.lastname: Wong
authors.affiliation: Center for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland.
authors.forename: Hong
authors.initials: H
authors.lastname: Chen
authors.affiliation: Center for Human Proteomics, Royal College of Surgeons in Ireland, Dublin, Ireland.
authors.forename: Edith
authors.initials: E
authors.lastname: Gould
authors.affiliation: Monoclonal Antibodies Unit, Biotechnology Programme, Spanish National Cancer Research Center, Madrid, Spain.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Roncador
authors.affiliation: Department of Hematology, John Radcliffe Hospital, Oxford, UK.
authors.forename: Chris
authors.initials: C
authors.lastname: Hatton
authors.affiliation: Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, UK.
authors.forename: Amanda P
authors.initials: AP
authors.lastname: Anderson
authors.affiliation: Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, UK.
authors.forename: Alison H
authors.initials: AH
authors.lastname: Banham
authors.affiliation: Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, UK.
authors.forename: Karen
authors.initials: K
authors.lastname: Pulford
keywords: ALCL; FADD; PTCL; autoantigen; lymphoma; pFADD